Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$18.44 - $26.41 $227,162 - $325,344
12,319 Added 71.06%
29,656 $601,000
Q4 2023

Feb 07, 2024

BUY
$12.64 - $30.11 $219,139 - $522,017
17,337 New
17,337 $390,000
Q3 2022

Nov 10, 2022

BUY
$16.33 - $51.06 $101,686 - $317,950
6,227 New
6,227 $260,000
Q4 2021

Feb 09, 2022

SELL
$36.77 - $90.91 $141,785 - $350,548
-3,856 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$41.79 - $135.3 $940,442 - $3.04 Million
-22,504 Reduced 85.37%
3,856 $239,000
Q2 2021

Aug 12, 2021

SELL
$32.15 - $89.72 $7,298 - $20,366
-227 Reduced 0.85%
26,360 $2.25 Million
Q1 2021

May 14, 2021

SELL
$7.09 - $87.95 $15,335 - $190,235
-2,163 Reduced 7.52%
26,587 $1.19 Million
Q4 2020

Feb 25, 2021

BUY
$6.79 - $12.25 $195,212 - $352,187
28,750 New
28,750 $196,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $116M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.